Pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia.
Standard
Pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia. / Roesch-Ely, D; Göhring, K; Gruschka, P; Kaiser, S; Pfüller, U; Burlon, Marc; Weisbrod, M.
In: PHARMACOPSYCHIATRY, Vol. 39, No. 3, 3, 2006, p. 115-116.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia.
AU - Roesch-Ely, D
AU - Göhring, K
AU - Gruschka, P
AU - Kaiser, S
AU - Pfüller, U
AU - Burlon, Marc
AU - Weisbrod, M
PY - 2006
Y1 - 2006
N2 - Negative and cognitive symptoms of schizophrenia are associated with a hypodopaminergic state in the frontal cortex and do not respond to neuroleptics equally well as positive symptoms. Therefore pharmacological strategies, which increase dopamine metabolism in the mesocortical pathways, may prove beneficial to ameliorate these symptoms. We report on a case of a patient with paranoid schizophrenia, who still presented negative and depressive symptoms during treatment with amisulpride for more than 6 weeks. We prescribed pergolide (a mixed D1/D2 agonist) as adjuvant therapy to treat these symptoms. The patient showed an improvement of global psychopathology, decrease of negative and depressive symptoms, while no changes in positive symptoms nor EPS were present. For this patient, the adjuvant therapy of pergolide to amisulpride constituted a valid pharmacological approach to treat negative and depressive symptoms of schizophrenia, without increasing positive symptoms.
AB - Negative and cognitive symptoms of schizophrenia are associated with a hypodopaminergic state in the frontal cortex and do not respond to neuroleptics equally well as positive symptoms. Therefore pharmacological strategies, which increase dopamine metabolism in the mesocortical pathways, may prove beneficial to ameliorate these symptoms. We report on a case of a patient with paranoid schizophrenia, who still presented negative and depressive symptoms during treatment with amisulpride for more than 6 weeks. We prescribed pergolide (a mixed D1/D2 agonist) as adjuvant therapy to treat these symptoms. The patient showed an improvement of global psychopathology, decrease of negative and depressive symptoms, while no changes in positive symptoms nor EPS were present. For this patient, the adjuvant therapy of pergolide to amisulpride constituted a valid pharmacological approach to treat negative and depressive symptoms of schizophrenia, without increasing positive symptoms.
M3 - SCORING: Zeitschriftenaufsatz
VL - 39
SP - 115
EP - 116
JO - PHARMACOPSYCHIATRY
JF - PHARMACOPSYCHIATRY
SN - 0176-3679
IS - 3
M1 - 3
ER -